COVID-19 and Kids: The Case for Vaccinating Younger Children in Canada

Last modified by Jose Gauthier on 2021/10/29 21:01

While severe acute illness from SARS-CoV-2 infection in children (i.e. COVID-19) is rarely severe, when determining public health policy, we must consider additional downstream effects of infection in children. Important additional considerations include but are not limited to: 1) multisystem inflammatory syndrome in children (MIS-C); 2) post-COVID-conditions (sometimes called long-COVID); 3) mental health implications of school closures; 4) potential for transmission to other household members. These elements all must be considered when determining vaccination and other relevant strategies that may be employed to mitigate infection in children.

Following this webinar attendees should:

1.      Understand why preventing pediatric SARS-CoV-2 infection is important

2.      Understand what MIS-C is and why it is a concern

3.      Be aware of what the post-COVID-condition looks like and how common it is in children

Dr. Stephen Freedman

Professor of Pediatrics and Emergency Medicine @ Alberta Children’s Hospital Foundation

Professor in Child Health and Wellness @ Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary

Dr. Freedman is Professor of Pediatrics and Emergency Medicine at the University of Calgary. He completed his residency at The Hospital for Sick Children (Toronto) in 2000 and a pediatric emergency medicine fellowship in 2003 at Children’s Memorial Hospital (Chicago). He obtained a Master’s of Science in Clinical Investigation at Northwestern University. He is currently the Past-Chair of Pediatric Emergency Research Canada and has been the Alberta Children’s Hospital Foundation Professor in Child Health and Wellness since 2016. His research focus is on applying clinical research to improve outcomes in children seeking emergency department care. His focus is on the use of innovative, multidisciplinary approaches to solve complex problems. He has published over 190 peer-reviewed manuscripts and is the principal investigator on numerous multicentre clinical trials with funding support from CIHR and the NIH. Most recently he received CIHR, Public Health Agency of Canada and Health Canada funding to lead several multi-centre pediatric COVID-19 studies.


Dr. Jim Kellner

Clinician Primary Researcher @ Alberta Children’s Hospital

Professor, Department of Pediatrics; Community Health Sciences; Microbiology; Immunology & Infectious Diseases @ University of Calgary

After a decade as the Head of Pediatrics in Calgary (2008-2018), Dr. Kellner has returned to focusing academic service on vaccine preventable infections through research and advisory work. Since 2020, his main focus has been SARS-CoV-2 infections and the COVID-19 pandemic. He is a member of the federal COVID-19 Immunity Task Force Leadership Group (www.covid19immunitytaskforce.ca) and Co-Chair of the Task Force’s Field Studies Working Party. In research, Dr. Kellner is leading the multi-faceted Alberta Childhood COVID-19 Cohort (AB3C) Study (www.ucalgary.ca/covidinkids). He is also leading local participation in a national COVID-19 vaccine safety program and clinical trials for COVID-19 vaccines for children.

Click here to download the webinar participation certificate.

Tags:
Created by Rachel Van Woezik on 2021/09/28 18:57